Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review and Meta-analysis |
Ding, Hui
(Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center)
Yang, Li (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Du, Wan (Otolaryngological Department, The Second Hospital of Lanzhou University) Teng, Yang (The People's Hospital of Rizhao Donggang Qu) Fu, Sheng-Jun (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Tao, Yan (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Lu, Jian-Zhong (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) Wang, Zhi-Ping (Institute of Urology, Key Laboratory of Diseases of Urological System, Gansu Province, Gansu Nephro-Urological Clinical Center) |
1 | Adler RA (2011). Management of osteoporosis in men onandrogen deprivation therapy. Maturitas, 68, 143-7. DOI ScienceOn |
2 | Balasch J (2003). Sex steroids and bone: current perspectives. Hum Reprod Update, 9, 207-22. DOI ScienceOn |
3 | Bhoopalam N, Campbell SC, Moritz T, et al (2009). Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol, 182, 2257-64. DOI ScienceOn |
4 | Bolla M (1999). Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol, 35, 23-5. DOI ScienceOn |
5 | Brufsky AM (2008). Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist, 13, 187-95. DOI ScienceOn |
6 | Casey R, Gesztesi Z, Rochford J (2010). Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol, 17, 5170-7. |
7 | Eriksson S, Eriksson A, Stege R, et al (1995). Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int, 57, 97-9. DOI ScienceOn |
8 | Frydenberg M, Stricker PD, Kaye KW (1997). Prostate cancer diagnosis and management. Lancet, 349, 1681-7. DOI ScienceOn |
9 | Greenspan SL, Nelson JB, Trump DL, et al (2007). Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med, 146, 416-24. DOI |
10 | Grivas N, Hastazeris K, Kafarakis V, et al (2012). Prostate cancer epidemiology in a rural area of North Western Greece. Asian Pac J Cancer Prev, 13, 999-1002. DOI ScienceOn |
11 | Higano CS (2004). Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am, 31, 331-52. DOI ScienceOn |
12 | Higano CS (2008). Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol, 5, 24-34. |
13 | Israeli RS, Rosenberg SJ, Saltzstein DR, et al (2007). The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer, 5, 271-7. DOI ScienceOn |
14 | Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. DOI ScienceOn |
15 | Magno C, Anastasi G, Morabito N, et al (2005). Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol, 47, 575-80. DOI ScienceOn |
16 | Maillefert JF, Sibilia J, Michel F, et al (1999). Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol, 161, 1219-22. DOI ScienceOn |
17 | Manolagas SC, Kousteni S, Jilka RL (2002). Sex steroids and bone. Recent Prog Horm Res, 57, 385-409. DOI ScienceOn |
18 | Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8. DOI ScienceOn |
19 | Michaud LB (2010). Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm, 67, S20-30. DOI ScienceOn |
20 | Michaelson MD, Kaufman DS, Lee H, et al (2007). Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol, 25, 1038-42. DOI ScienceOn |
21 | Morabito N, Gaudio A, Lasco A, et al (2004). Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res, 19, 1766-70. DOI ScienceOn |
22 | Riggs BL, Khosla S, Melton LJ, 3rd (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev, 23, 279-302. DOI ScienceOn |
23 | Ryan CW, Huo D, Demers LM, et al (2006). Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol, 176, 972-8. DOI ScienceOn |
24 | Ryan CW, Huo D, Bylow K, et al (2007). Suppression of bone density loss and bone turnover in patients with hormonesensitive prostate cancer and receiving zoledronic acid. BJU Int, 100, 70-5. DOI ScienceOn |
25 | Serpa NA, Tobias-Machado M, Esteves MA, et al (2010). A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol, 10, 9. DOI ScienceOn |
26 | Sharifi N, Gulley J L, Dahut W L (2005). Androgen deprivation therapy for prostate cancer. Jama, 294, 238-44. DOI ScienceOn |
27 | Smith MR, McGovern FJ, Zietman AL, et al (2001). Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345, 948-55. DOI ScienceOn |
28 | Smith MR, Morton RA, Barnette KG, et al (2010). Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol, 184, 1316-21. DOI ScienceOn |
29 | Smith MR, Eastham J, Gleason DM, et al (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 169, 2008-12. DOI ScienceOn |
30 | Smith MR, Saad F, Egerdie B, et al (2009). Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol, 182, 2670-5. DOI ScienceOn |
31 | Taxel P, Dowsett R, Richter L, et al (2010). Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int, 106, 1473-6. DOI ScienceOn |
![]() |